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Improving the management of 
Inherited Retinal Dystrophies 
by targeted sequencing of a 
population-specific gene panel
Nereida Bravo-Gil1,2,*, Cristina Méndez-Vidal1,2,*, Laura Romero-Pérez1,  
María González-del Pozo1,2, Enrique Rodríguez-de la Rúa3, Joaquín Dopazo2,4,5, 
Salud Borrego1,2 & Guillermo Antiñolo1,2
Next-generation sequencing (NGS) has overcome important limitations to the molecular diagnosis 
of Inherited Retinal Dystrophies (IRD) such as the high clinical and genetic heterogeneity and the 
overlapping phenotypes. The purpose of this study was the identification of the genetic defect in 32 
Spanish families with different forms of IRD. With that aim, we implemented a custom NGS panel 
comprising 64 IRD-associated genes in our population, and three disease-associated intronic regions. 
A total of 37 pathogenic mutations (14 novels) were found in 73% of IRD patients ranging from 50% for 
autosomal dominant cases, 75% for syndromic cases, 83% for autosomal recessive cases, and 100% for 
X-linked cases. Additionally, unexpected phenotype-genotype correlations were found in 6 probands, 
which led to the refinement of their clinical diagnoses. Furthermore, intra- and interfamilial phenotypic 
variability was observed in two cases. Moreover, two cases unsuccessfully analysed by exome 
sequencing were resolved by applying this panel. Our results demonstrate that this hypothesis-free 
approach based on frequently mutated, population-specific loci is highly cost-efficient for the routine 
diagnosis of this heterogeneous condition and allows the unbiased analysis of a miscellaneous cohort. 
The molecular information found here has aid clinical diagnosis and has improved genetic counselling 
and patient management.
Inherited Retinal Dystrophies (IRD) are a heterogeneous group of diseases involving progressive degeneration 
of retinal photoreceptors. The most common form of IRD is Retinitis Pigmentosa (RP; MIM #268000), affect-
ing 1 in ~4,000 individuals1. This condition is usually inherited as an autosomal recessive (ARRP), autosomal 
dominant (ADRP), X-linked recessive (XLRP) or sporadic/simplex trait (SRP), although rarer forms such as 
X-linked semi-dominant, mitochondrial and digenic have also been described2. Rod photoreceptors are the first 
cells affected in RP, followed by cones dysfunction in later stages of the disease. For this reason, other types of 
IRD as Cone-Rod dystrophies (CRD) and Leber Congenital Amaurosis (LCA), implicating both cones and rods 
photoreceptors, may present overlapping phenotypes with RP3 at their end-stages. Likewise, macular dystrophies 
as some cases of Stargardt disease (STGD) and Retinoschisis (RS) at atrophic stages can be difficult to diagnose 
at older ages. Additionally, there are syndromic forms of RP in which the disease is not limited to the eye, being 
Usher Syndrome (USH) and Bardet-Biedl Syndrome (BBS) the most prevalent of those disorders1,2.
This phenotypic overlap added to the high loci heterogeneity, with more than 200 IRD-associated genes and 
the fact that mutations in multiple genes can converge in the same phenotype4, make the clinical and molecular 
diagnosis of IRD an extremely difficult task. The recently introduced next-generation sequencing (NGS) tech-
nologies have shown to be very advantageous for the molecular characterization of IRD families5–7. Currently, 
targeted analysis of disease-specific candidate genes allows a better functional interpretation of sequence 
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variations, and overcomes limitations of computational analysis related to the large amount of data generated by 
high-throughput sequencing platforms6,8,9. Despite clear improvements have been made, further optimization 
of current gene panels and bioinformatics pipelines implicating CNVs and other variants difficult to analyse, are 
needed to maximize diagnostic yield.
The prevalence of causative genes and mutations may vary considerably among different populations10. Thus, 
we developed a capture panel covering 64 retinal genes previously reported in IRD Spanish families. That panel 
was used to identify the genetic cause of the retinal disease in 32 unrelated Spanish families. Pathogenic mutations 
were found in 22 of the unsolved families (73%), whereas a conclusive diagnosis was achieved in 21 of them. That 
results in a diagnostic rate of 70%, demonstrating the validity of our genomic approach for genetic diagnosis of 
IRD.
Results
Clinical Assessment. The 32 index patients showed various clinical manifestations (see Supplementary 
Table S1). A total of 15 cases out of 32 presented night blindness as the first symptom, whereas the remaining 
families showed other initial symptoms such as decreased visual acuity or visual field constriction. Best corrected 
visual acuity (BCVA) of affected individuals ranged from 0.025 to 0.8. Moreover, age of onset and subsequent fun-
dus appearance were different among families. All those clinical features together with the pedigree information, 
led to initially classify 10 families as arRP, 6 as adRP, 4 as USH, 4 as BBS, 2 as sRP, 2 as RS, 2 as STGD, 1 as XLRP 
and 1 as LCA. After the genetic findings, 6 cases were clinically reassessed.
NGS data quality. A capture panel covering 64 retinal disease genes was used to identify the genetic 
cause of 32 IRD patients. On average, the mean coverage was 409× with 99% of reads covered > 70× and 82% 
> 200× . Different average coverages were achieved for the 64 targeted genes, ranging from 247× (NRL) to 565× 
(BBS12). Of note, the mean coverage for the hot spot exon ORF15 of RPGR, a region typically problematic for 
enrichment-based NGS methods, was average 389× and therefore suitable for variant calling. Application of 
variant calling, filtering and annotation of the sequencing data was performed as described above. This process 
concluded with an average of three candidate variants per sample to be validated and cosegregated by Sanger 
Sequencing. Mean output data for each step of the analysis pipeline are shown in Supplementary Fig. S1.
Validation of the panel-based approach. For validation purposes, we used two previously solved fam-
ilies (RP15 and RP234), harbouring one and three known variants, respectively, as positive controls for our data 
analysis pipeline. These known mutations were correctly called and filtered, being the causal mutations high-
lighted after the bioinformatics analysis and demonstrating the diagnostic reliability of our approach. This is espe-
cially significant considering that one of the mutations of the positive control family RP234 was a Copy Number 
Variation (CNV) involving exon 12 of EYS11. In addition, the 21 variants previously detected by other techniques 
were also used to test the variant detection sensitivity of our study (Table 1). All these variants were also efficiently 
redetected by this platform, indicating a mutation detection rate of 100%.
Identification of pathogenic mutations in unsolved families. Sanger sequencing was performed 
to validate each variant and to carry out family cosegregation analyses. Moreover, when necessary, MLPA was 
performed to confirm presence of CNVs. These studies resulted in 37 potential pathogenic mutations in 22 out 
of the 30 families (73%) (Table 1; Figs 1 and 2). However, a full diagnosis was not achieved in one of these fam-
ilies (RP264) due to the nature of the detected mutation (Table 1), in silico predictions (Table 2) and the lim-
ited number of available family members for segregation analysis (Fig. 2), remaining a diagnostic rate of 70%. 
Fourteen of these variants were novel and absent in public databases as dbSNP, 1000 Genomes, EVS, ExAC and 
Database Genomic Variants (DGV), whereas 19 were previously reported as IRD causal mutations. Remarkably, 
a presumed pathogenic mutation in the dominant gene CA4 (c.206G > A; p.Arg69His) was detected in the USH 
family RP236, but this variant did not conform to the recessive mode of inheritance of the family. Moreover, this 
mutation did not cosegregate with the disease since it was absent in affected individual II:3 while unaffected indi-
viduals I:2, II:4 and II:5 were heterozygous.
Detected candidate variants included 2 CNVs, 19 missense, 3 nonsense, 8 frameshift, 3 splicing and 2 intronic 
mutations. Novel frameshift and point mutations were absent in 200 matched controls sequenced by Sanger 
and in 267 healthy exomes from the Medical Genome Project10. The specific coverage for all detected variants is 
shown in Table 1 and in silico predictions in Table 2.
The most frequent mutated genes of this study were USH2A and BBS1, which appear in four and two of 
the solved cases, respectively. The rest of mutated genes were ABCA4, BBS10, BBS2, CDH23, CEP290, CRB1, 
IMPDH1, NMNAT1, NR2E3, PRPF3, PRPF8, RDH12, RP1, RPGR, CRX and RS1, all involved only in one family.
Genotype-phenotype correlations and clinical refinements. The extreme phenotypic overlapping of 
IRD makes it difficult to establish clear clinical diagnoses. Most cases showed consistent results between clinical 
and genetic data, with the exception of families RP134, RP353, RP193, RP277 and RP522 (see Supplementary 
Table S1).
The mode of inheritance of family RP134 could not be assigned with complete confidence until the genetic 
diagnose was achieved. Our results showed that this family harboured a novel RPGR mutation that cosegregated 
in all members following a semidominant X-linked inheritance. Clinical reassessment showed that all female car-
riers presented visual impairments ranging from high myopia to mild RP, while males showed early onset disease 
with more severe symptoms. Families RP277 and RP353 had been diagnosed of arRP, but we suspected causal 
mutations in genes CRB1 and RDH12, respectively. After reassessment, a diagnosis of LCA or early CRD was 
considered in both index patients. Affected member of family RP193 was diagnosed of arRP but the detection of 
a segregating homozygous mutation in CEP290 led to the re-evaluation of the family, since mutations in this gene 
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have been associated with severe ciliopathies such as BBS, Joubert syndrome, Meckel syndrome, Senior-Loken 
syndrome and LCA. The visual acuity decrease at 28 years old and the congenital nystagmus led to rectify the ini-
tial diagnosis of RP to a late onset form of LCA. Finally, affected individuals of family RP522 had received diverse 
clinical diagnoses, from retinoschisis to unspecified macular dystrophy and cone dystrophy. Targeted sequencing 
allowed us to detect a heterozygous CNV in CRX, a gene associated with dominant LCA, allowing a genetic diag-
nosis and clinical reclassification of this family.
Phenotypic variability. The age of onset, the progression and the severity of the symptoms can vary 
greatly among affected individuals of retinal diseases even in the same family. Intrafamilial phenotypic varia-
bility was observed in family RP435 since index patient showed a severe form of IRD with early visual impair-
ments, decreased visual field as first symptom and abolished ERG (see Supplementary Table S1), whereas affected 
Fam 
(RP) Gene Nt Change Prot Change Status
Cvg 
Mut Ref.
134 RPGR c.3168G > C p.R1056S Hem 320 Novel
234# EYS c.1971delT (*) p.S658Vfs*4 (*) Hem 360 11
c.(1766 + 1_1767 − 1)_
(2023 + 1_2024 − 1)del (*) NA Het –
258 NR2E3 c.194_202del p.N65_C67del Het 136 35
c.967dupA p.M323Nfs*18 Het 400 Novel
298 ABCA4 c.3386G > T (*) p.R1129L (*) Het 392 36
c.1819G > C p.G607R Het 443 37
356 USH2A c.10272_10273dupA (*) p.C3425Ffs*4 (*) Het 739 38
c.10712C > T p.T3571M Het 721
435 USH2A c.2276G > T (*) p.C759F (*) Het 899 39
c.12569T > C p.V4190A Het 813 Novel
CRB1 c.3988G > T (*) p.E1330* (*) Het 738 40
15# RPGR c.2405-2406delAG (*) p.E802Gfs*32 (*) Hem 174 41
95 BBS1 c.1169T > G p.M390R Het 401 23
c.1474-2A > G NA Het 277 Novel
353 CRB1 c.2290C > T (*) p.R764C (*) Het 699 42
c.2579delA p.N861Ifs*21 Het 860 Novel
359 PRPF8 c.6994dupG p.D2332Gfs*53 Het 363 Novel
488 BBS1 c.1169T > G (*) p.M390R (*) Het 629 23
c.118delT p.C40Afs*2 Het 676 Novel
512 RS1 c.522 + 1G > C NA Hem 289 Novel
63 IMPDH1 c.402 + 57G > A NA Het 139 43
82 RP1 c.368_369dup p.P124Afs*20 Hom 269 44
118 CDH23 c.5816G > A p.R1939K Het 169 Novel
c.7221C > A p.Y2407* Het 180 45
157 NMNAT1 c.197G > A p.R66Q Het 467 ExAC
c.769G > A p.E257K Het 421 46
193 CEP290 c.5254C > T p.R1752W Hom 173 47
236 USH2A c.754G > T p.G252C Het 346 Novel
c.4474G > T p.E1492* Het 329 48
c.(9258 + 1_9259 − 1)_
(11389 + 1_11390 − 1)del NA Het – Novel
247 USH2A c.6937G > T p.G2313C Het 294 Rs1
c.1000C > T (*) p.R334W (*) Het 304 49
264 PRPF3 c.1283-60_1283-57delATAT NA Het 29 Rs2
277 RDH12 c.295C > A (*) p.L99I (*) Het 292 50
c.481C > T p.R161W Het 313 51
449 BBS2 c.1780C > T p.R594* Het 166 Novel
c.471 + 1G > A NA Het 147 Novel
519 BBS10 c.1244delA p.H415Lfs*16 Het 258 52
c.273C > G p.C91W Het 283 53
522 CRX c.(100 + 1_101 − 1)_(*1097_?)del NA Het – Novel
Table 1.  Causative variants detected in all solved families. Cvg Mut: coverage for each position. Asterisks 
“(*)”: variants previously detected by other techniques. Pads “#”: families solved prior to this study. Rs1: 
rs199840367 and rs2: rs66790680. ExAC: Variant present in the Exome Aggregation Consortium.
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Figure 1. Segregation analysis of identified variants in the families with an initial clinical diagnosis of 
RP. (a–d) Pedigrees of arRP families. (e) Pedigrees of the family RP435. This family exhibited intrafamilial 
phenotypic variability. The phenotype of the index patient was more consistent with RP with early macular 
involvement (checkered symbol) while the diagnosis of arRP was confirmed in her affected brother (individual 
II:3) (solid symbol). (f–h) Pedigrees of families with a preliminary clinical diagnosis of arRP that has been 
reclassified to CRD. (i) Pedigree of an sporadic adRP family harboring a de novo frameshift mutation in PRPF8. 
(j) Pedigree of the adRP family RP63. (k) Pedigree of the partially dominant X-linked RP in which the oldest 
female carrier (II:8) showed clinical features of RP and the youngest (III:1, III:2 and III:4) had high myopia. 
Index patients are indicated with a black arrow. NA means non available DNA sample.
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Figure 2. Segregation analysis of identified variants in the families with an initial clinical diagnosis of 
diverse retinal phenotypes. (a) Pedigree of the LCA family RP157. (b) Pedigree of the dominant LCA family 
RP522 harboring the heterozygous deletion of exons 3 and 4 in the CRX gene. (c) Pedigree of the STGD family 
RP298. (d–f) Pedigrees of the Usher Syndrome families. (g,h) Pedigrees of the Bardet-Biedl Syndrome families. 
(i) Pedigree of the related families RP264 and RP449. The index patient of the family RP449 (individual IV:2) 
received a clinical diagnosis of Bardet-Biedl Syndrome (checkered symbol) while the RP264 patients (II:4, III:4, 
III:5 and III:7) received a clinical diagnosis of adRP (solid symbols). (j) Pedigree of the retinoschisis family RP 
512. Index patients are indicated with a black arrow. NA means non available DNA sample.
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individual II:3 showed a milder IRD with a later age of onset and slower disease progression. Two USH2A variants 
were detected in this family and both cosegregated with the disease in compound heterozygosity. However, those 
variants did not explain by themselves the early onset of symptoms of the index patient and the variations of 
phenotype between both affected members. Considering the presence of phenotype modifiers, we segregated the 
previously detected CRB1 null mutation c.3988G > T in available family members (Fig. 1), confirming that the 
index patient carried three pathogenic alleles and individual II:3 only two in USH2A. Secondly, families RP95 and 
RP488 shared the BBS1 mutation p.M390R which cosegregated with the disease in compound heterozygosity in 
both cases (Figs 1 and 2). However, family RP95 was diagnosed of sRP and family RP488 of BBS. Given that BBS1 
is a common BBS gene, family RP95 was subjected to clinical reassessment but no extraocular symptoms were 
detected, confirming non-syndromic RP in the index patient. Therefore, both families presented interfamilial 
variability caused by the same pathogenic allele.
Discussion
For genetically and clinically heterogeneous diseases, where many different genes are involved without a major 
contribution of a single gene, parallel testing of several genes substantially increases the diagnostic yield and 
represents the most cost effective diagnostic choice12. In this study, we sequenced 32 IRD families using a cus-
tomized panel covering 64 retinal genes. Reanalysis by gene panel sequencing of two of these families (RP258 
and RP82), previously unsuccessfully studied by WES, led to the identification of disease-causing mutations 
in RP1 (c.368_369dup; p.Pro124Alafs*20) and NR2E3 (c.194_202del; p.Asn65_Cys67del and c.967dupA; 
p.Met323Asnfs*18). Although sequence data quality of WES was optimal, these variants were filtered out during 
bioinformatic analysis due to low coverage of these specific regions, supporting the fact that gene panel sequenc-
ing provides advantage over exome sequencing and should be the primary choice in a NGS-based diagnostic 
routine for highly heterogeneous disorders6.
Indeed, our panel-based next generation sequencing approach allowed us to detect all previously detected 
variants in the testing cohort yielding a diagnostic rate of 70% in a heterogeneous group of families with retinal 
degeneration. However, this percentage could be increased up to 73% if the pathogenicity of the intronic PRPF3 
variant is fully demonstrated. A total of 37 different mutations were found, 14 (37.8%) of which were novel var-
iants newly associated with IRD in 9 genes that would have been missed by other standard approaches targeting 
only known alleles. The gene USH2A was more frequently affected than other genes (4 families), which is consist-
ent with other recent reports13. However, we have to take into account that all our samples were previously tested 
and excluded for mutation in EYS, the most prevalent gene related to autosomal recessive retinal degeneration in 
our population14–16.
The selected group of patients included challenging cases for NGS data analysis such as simplex and autosomal 
dominant cases or cases with a poorly defined clinical picture. Remarkably, we found a possible dominant de-novo 
mutation in one case with sporadic RP. These results further support the role of this type of mutations, usually 
underestimated, in the development of simplex cases of RP which have major implications for genetic counselling 
of these families. In this light, our panel provided a high diagnostic yield regardless of the relatively small size of 
the panel (only 64 genes), mode of inheritance or clinical history. This unbiased strategy is particularly important 
for clinical genetics centres that can offer genetic diagnosis for a greater number of rare diseases even when the 
number of samples is small. The high yield may be the result of analyzing data for de novo mutations and CNVs 
that generally remain challenging despite the improvements to NGS technologies and CNV-detecting tools. This 
yield is comparable to other panels for the molecular diagnosis of retinal degeneration that simultaneously ana-
lyse a higher number of genes17. Although, the number of genes included in this panel will be higher as research 
evolves and more genes associated to IRD will be identified, these results indicate that increasing the number of 
genes in the panel may not substantially improve the diagnostic yield for a particular population. Those cases not 
resolved at this stage, may be investigated by applying clinical or whole exome sequencing.
CNVs are a significant event in the appearance of IRD but intrinsic methodology limitations commonly result 
in an underestimation of their allele frequencies16. Specific CNVs were detected in three patients: one involving 
Family 
(RP) Gene Mutation Polyphen (score) Sift (score) NNSPLICE HSF Mutation taster
134 RPGR p.R1056S Benign (0.347) Damaging (0.02) – –
435 USH2A p.V4190A Damaging (1) Damaging (0) – –
95 BBS1 c.1474-2A > G – – Acceptor-site broken Acceptor-site broken Acceptor-site broken
512 RS1 c.522 + 1G > C – – Donor-site broken Probably no impact Donor-site broken
63 IMPDH1 c.402 + 57G > A – – Probably no impact Probably no impact Donor-site gained
118 CDH23 p.R1939K Damaging (0.997 ) Tolerated (0.56) – –
157 NMNAT1 p.R66Q Damaging (0.962) Damaging (0) – –
193 CEP290 p.R1752W Damaging (1) Damaging (0.01) – –
236 USH2A p.G252C Damaging (0.999) Damaging (0.01) – –
247 USH2A p.G2313C Damaging (1) Damaging (0) – –
264 PRPF3 c.1283-60_1283-57del – – Probably no impact Probably no impact Probably no impact
449 BBS2 c.471 + 1G > A – – Donor-site broken Donor-site broken Donor-site broken
Table 2.  In silico predictions for missense and splicing novel and non disease-associated mutations.
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exon 12 of EYS in a control patient, one in CRX (deletion of exons 3 and 4), a dominant LCA-associated gene, in a 
family (RP 522) with a poorly defined clinical history and another one in USH2A (deletion of exons 47–58) in an 
Usher patient (RP 236) who also presented two further USH2A variants and an adRP-associated mutation in CA4 
(c.206G > A; p.Arg69His)18. A toxic gain of function has been attributed to the CA4 variant, leading to impaired 
trafficking of the CA4 protein, ER stress and apoptosis19. Nevertheless, this mutation neither conformed to the 
recessive mode of inheritance nor cosegregated with the disease in this family. In addition, we ruled out the possi-
bility that this variant was acting as a modifier of the phenotype in this family since both affected siblings showed 
the same clinical features but only one harboured the CA4 variant in heterozygous state. Those facts exclude the 
role of the CA4 mutation in the IRD of family RP 236 and question its pathogenicity. These results suggest that the 
CNV found in USH2A, c.(9258 + 1_9259 − 1)_(11389 + 1_11390 − 1)del, in compound heterozygosity with the 
mutation c.4474G > T is the most likely cause of the disease.
The family RP193 harbouring the homozygous CEP290 mutation c.5254C > T (p.R1752W), was initially diag-
nosed of arRP. This variant was previously reported by Eisenberger and coauthors as a third allele in a LCA fam-
ily20. Here, the mutation c.5254C > T in the CEP290 gene was found in association with a milder phenotype than 
typical LCA. The clinical results reported here are consistent with a previous study describing LCA patients with 
CEP290 mutations21. Although most patients studied showed a severe visual acuity loss at first decade, they could 
observe a significant group of patients with atypical visual acuity preservation at later ages. Although more than 
100 mutations in CEP290 have been identified, no clear genotype-phenotype correlations have been established22. 
The results obtained in this study extend the phenotypic spectrum for CEP290 mutations.
Six probands out of 22 individuals with positive molecular results showed inconsistent results between the 
molecular findings and their initial clinical diagnoses. Reassessment of the clinical information resulted in refine-
ment of the clinical diagnoses to other retinal-related diseases or syndromes. This high clinical reclassifications 
rate (27%) is particularly important for the accurate diagnosis of this group of heterogeneous disorders. In addi-
tion, families showing clinical variability also complicate a proper diagnosis. Two families demonstrated pheno-
typic variability under the same mutant allele. The non-syndromic RP family RP95 and the BBS family RP488 
harboured the common p.Met390Arg variant which causes 80% of BBS cases harboring mutations in BBS123. 
Also, it has been reported that BBS1 can cause either BBS or non-syndromic RP when mutated24. Therefore, 
our results confirmed those previous reports with two mutations in BBS1 causing arRP. Moreover, a potential 
epistastic interaction was observed in family RP435. In addition to the identification of two mutations in USH2A 
as the most likely cause of the disease, data analysis and family segregation showed the presence of a heterozy-
gous variant (c.3988G > T) in the gene CRB1 only in patient II:6 and in her unaffected mother (I:2). The age 
of disease-onset was significantly different between the two affected siblings. While patient II:6, with the more 
severe phenotype (arRP with early macular involvement), presented the first symptoms shortly after birth, her 
affected sibling (II:3) showed a milder phenotype more typical of USH2A-associated mutations. We hypothesize 
that this phenomenon may be due to an epistatic effect of USH2A and CRB1 mutations and may provide an expla-
nation for the intrafamilial phenotypic variations observed in this family.
Analysis of intronic sequences flanking targeted exons showed two individuals harbouring low frequency 
variants in regions relatively distant (57–60 bp) from the natural donor and acceptor splice sites typically spand-
ing intervals of 10 and 28 bases in length. Sequence variants affecting these sites or binding sites for splicing 
regulatory elements, which reside over a range of distances from the corresponding natural splice sites, have been 
shown to contribute to aberrant splicing and pathogenic phenotypes25. The intronic variant in IMPDH1 was pre-
dicted to affect the splicing by creating a new donor-site according to MutationTaster tool. However, the intronic 
mutation of PRPF3 was predicted to be benign by the in silico prediction tools used. In this regard, it has been 
reported that in some instances, functional non-canonical cryptic splicing sites can be challenging to identify by 
in silico prediction tools, because they use to be less well conserved than natural splice sites. In addition, these 
tools can occasionally provide conflicting results due to the use of different algorithms. Therefore, bioinformatic 
predictions should be complemented with additional studies to elucidate the pathogenic role of these variants in 
the RP of families 63 and 264. Despite this, the extensive cosegregation studies involving ten family members, the 
low MAF of the IMPDH1 variant in public databases and its absence in 400 chromosomes of control population, 
let us to consider the IMPDH1 mutation as likely causative in family RP 63.
In summary, although IRD panels including a larger number of genes have been successfully applied, we 
believe that sequencing diagnostic panels, targeting only genes and regions affecting a particular population, 
should represent the primary choice in a NGS-based diagnostic routing for highly heterogeneous disorders, fol-
lowed by exome or genome sequencing of unsolved cases. Although research is in progress26, there is still no 
established treatment for hereditary blindness. The molecular findings reported here expand our understanding 
of retinal degeneration and greatly improve the genetic counselling management of our patient with IRD.
Methods
Sample collection. This study involved 208 Caucasian individuals belonging to 32 families selected on the 
basis of the phenotype and previous molecular genetics analyses. All affected individuals underwent a thorough 
ophthalmic evaluation as described elsewhere27 and were derived from the Ophthalmology Department to the 
Genetic, Reproduction and Fetal Medicine Department. Moreover, a group of 467 control individuals, which 
comprised unselected, unrelated race-, age-, and gender-matched Spanish individuals, was recruited. The research 
was conducted in accordance with the tenets of the Declaration of Helsinki28 and all experimental protocols 
were approved by the Institutional Review Boards of the University Hospital Virgen del Rocio (Spain). Written 
informed consent was obtained from all participants. Genomic DNA of all subjects was isolated from peripheral 
blood using standard procedures. DNA samples of index patients were processed for targeted sequencing.
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Previous genetic analyses. DNA sample from index patients was first analysed by multiple approaches for 
the identification of causative variants, including an available microarray analysis (Asper Biotech, Tartu, Estonia), 
a custom genome resequencing microarray11, whole exome sequencing and direct sequencing15 and multiplex 
ligation dependent probe amplification (MLPA)16 of EYS. Pathogenic variants detected by these techniques are 
marked in Table 1. Of note, no candidate causal mutations were found in two of the families sequenced by whole 
exome sequencing (RP82 and RP258).
Two of the IRD families included in this study (RP15 and RP234) were previously solved by these previous 
techniques and were used as positive controls. The remaining thirty families were still unsolved. Among them, 12 
were found to carry 21 likely disease causing mutations detected by the above methods (Table 1).
Design of the capture panel. The detection rate by targeted sequencing is substantially affected by 
population-specific mutation frequencies. Therefore, in order to select the most appropriate retinal genes for our 
population, we collected all mutated genes of our local cohort and performed an extensive literature review of 
genes with pathogenic mutation in Spanish population. This search was conducted using the following terms in 
PubMed: (Spain) AND (Retinal Dystrophies OR Retinal Degeneration OR Ciliopathies). These selection criteria 
resulted in 64 retinal genes (see Supplementary Table S2).
A custom IRD panel containing all coding exons plus 25 bp of intronic flanking sequences of the 64 selected 
genes was developed using SureDesign (www.agilent.com/genomics/suredesign). Moreover, deep intronic 
sequences of USH2A, CEP290 and OFD1 genes, containing prevalent pathogenic mutations, were also included 
(see Supplementary Table S2). The probes covered a total of 1106 exons with a total size of 311.683 Kbp.
Library preparation and targeted sequencing. The in-solution target enrichment was performed 
according to Agilent’s standard protocol for Illumina library preparation (SureSelectXT Target Enrichment System 
for Illumina Paired-end Sequencing Library) following the manufacturer’s instructions. Briefly, sheared DNA 
was hybridized with specific probes, and captured fragments were separated using streptavidin-coated magnetic 
beads and buffers. The selected regions were then PCR-amplified using Illumina PCR primers. Illumina librar-
ies were quantified using the Agilent 2100 Bioanalyzer (Agilent Technologies), qPCR and spectrophotometric 
measurements and the final products were sequenced in a MiSeq instrument using a v2 (300 cycles) reagent kit 
(Illumina).
Sequence data analysis. In order to identify causative mutations in the sequenced samples, we used our 
validated data analysis pipeline29 with some modifications. Sequence reads were mapped against the human 
genome reference (hg19) using SureCall software (Agilent, version 2.1). The coverage and the percentage of reads 
on target were analysed using the BEDtools package. SNVs and indels were called and filtered using GATK soft-
ware (version 1.4)30. Filtered variants with a coverage > 20× were annotated using Annovar31 and those with 
a MAF higher than 0.01 in at least one of the searchable databases (dbSNP, 1000 Genomes, Exome Variant 
Server (EVS), Exome Aggregation Consortium (ExAC) and an in-house developed database containing exome 
sequences from 267 control individuals32) were excluded. To detect known disease-associated mutations, the 
remaining variants were compared to human mutation databases such as HGMD and ClinVar using the TEAM 
tool (http://team.babelomics.org)33. The prioritization was performed using the BiERapp tool (http://bierapp.
babelomics.org)34, generating a list of candidate causative mutations.
Potential copy number variations (CNV) were identified by Surecall (Agilent) on mapped reads using the 
“pair analysis” option. Coverage of each target region of the sample of interest was internally compared to data 
of other samples of the same run. Deletions and duplications were reported if they were detected against at least 
> 50% of samples and had a score > 0.7. Identified CNVs were compared with structural variations present in the 
Database of Genomic Variants (DGV).
Pathogenicity assessment and validation of candidate variants. Sanger sequencing was used 
to validate and cosegregate candidate variants in available family members. Likewise, a screening of the novel 
changes in 200 matched control individuals was also carried out by direct sequencing. Additionally, the presence 
of all candidate variants were checked in the above mentioned database containing the exomes from 267 healthy 
controls of the Spanish population (The Medical Genome project, http://www.medicalgenomeproject.com/). The 
pathogenicity of novel SNVs was predicted by PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT 
(http://sift.bii.a-star.edu.sg) algorithms. Additionally, to estimate the effect of intronic mutations on the splic-
ing process we used NNSPLICE (http://www.fruitfly.org/seq_tools/splice.html), Mutation Taster (http://www.
mutationtaster.org/) and Human Splicing Finder (HSF; http://www.umd.be/HSF). The nomenclature of variants 
was adjusted to the Human Genome Variation Society (http://www.hgvs.org) guidelines using Mutalyzer (http://
www.LOVD.nl/mutalyzer).
CNVs were validated by multiplex ligation dependent probe amplification (MLPA). SALSA MLPA P361, P362 
and P221 were employed to analyse large rearrangements following manufacturer´s recommendations (MRC 
Holland, Amsterdam, The Netherlands).
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